[1]N. Mottet, et al. European Association of Urology. Guidelines on Prostate Cancer. 2019: 82. https://uroweb.org/guidelines/ (2019)
[2]转移性前列腺癌化疗中国专家共识.中华泌尿外科杂志 2017,38(3):161-165.[3]Virgo KS, et al. Second-Line Hormonal Therapy for Men With Chemotherapy-Naïve, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol. 2017;35(17):1952-1964.[4]Labrie, F. Combined blockade of testicular and locally made androgens in prostate cancer: a highly significant medical progress based upon intracrinology. J Steroid Biochem Mol Biol. 2015 Jan;145:144-56.[5]Montgomery RB et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008 Jun 1;68(11):4447-54.[6]Logothetis CJ, et al. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov. 2013;3:849–61.[7]Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet. 2000; 355:1491-8.[8]Kojima S et al. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy. J Urol 2004; 171(2 Pt 1):679-83.[9]Kucuk et al. Phase II trial of bicalutamide in patients with advanced prostate cancer in whom conventional hormonal therapy failed: a Southwest Oncology Group study (SWOG 9235). Urology 2001; 58(1):53-58.[10]Joyce et al. High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy. J Urol 1998;159(1):149-53.[11]Scher et al. Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. JCO 1997;15(8):2928-38.[12]L Klotz et al. An open-label, phase 2 trial of bicalutamide dose escalation from 50 mg to 150 mg in men with CAB and castration resistance. A Canadian Urology Research Consortium Study. Prostate Cancer Prostatic Dis. 2014 Dec;17(4):320-4[13]Fizazi K, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92.[14]Ryan CJ, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015; 16(2): 152-160 最新速递,3月11日下午14:00-15:30,三位泌尿外科大咖将为我们联袂奉上《抗击NM-CRPC的探索史及其治疗新进展》的主题分享,扫描下方二维码观看精彩内容。